Clinical Trials Details

S1800A LungMAP - SUBSTUDY (Lung)

A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer (LungMAP Non-Match SUBSTUDY)

Clinical Trial Categories

  • Cancers and Other Neoplasms